Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Jazz Pharmaceuticals PLC    JAZZ   IE00B4Q5ZN47

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
142.14(c) 148.5(c) 150.19(c) 149.8(c) 149.27 Last
414 673 878 556 787 439 630 005 173 126 Volume
-0.63% +4.47% +1.14% -0.26% -0.35% Change
More quotes
Financials ($)
Sales 2017 1 622 M
EBIT 2017 893 M
Net income 2017 377 M
Debt 2017 1 014 M
Yield 2017 -
Sales 2018 1 846 M
EBIT 2018 1 028 M
Net income 2018 539 M
Debt 2018 552 M
Yield 2018 -
P/E ratio 2017 25,42
P/E ratio 2018 18,37
EV / Sales2017 6,16x
EV / Sales2018 5,16x
Capitalization 8 981 M
More Financials
Company
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.Its product portfolio includes: XYREM, ERWINAZETM, PRIALT,... 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Surperformance© ratings of Jazz Pharmaceuticals PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on JAZZ PHARMACEUTICALS PLC
01/02 JAZZ PHARMACEUTICALS : to Present at the J.P. Morgan Healthcare Conference on Ja..
2017 JAZZ PHARMACEUTICALS : Submits New Drug Application for Solriamfetol (JZP-110) f..
2017 JAZZ PHARMACEUTICALS : Pennsylvania man admits to trading on tips about drug com..
2017 JAZZ PHARMACEUTICALS : to Present at the BMO Capital Markets Healthcare Conferen..
2017 JAZZ PHARMACEUTICALS : Announces Appointment Of Daniel Swisher As President And ..
2017 JAZZ PHARMACEUTICALS : Announces Participation in Three Upcoming Investor Confer..
2017 JAZZ PHARMACEUTICALS : Announces Third Quarter 2017 Financial Results
2017 JAZZ PHARMACEUTICALS : Submits Vyxeos™ Marketing Authorization Application..
2017 JAZZ PHARMACEUTICALS : to Highlight Hematology Research at ASH 2017 Annual Meeti..
2017 JAZZ PHARMACEUTICALS : to Report 2017 Third Quarter Financial Results on Novembe..
More news
Sector news : Specialty & Advanced Pharmaceuticals
12:09p EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
08:49a Allergan Pact Advances -- WSJ
08:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
12:18a Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on JAZZ PHARMACEUTICALS PLC 
JAZZ PHARMACEUTICALS - 2013
In an upward trend
BUY
More Strategies
Latest Tweets
08:49aRecent Analysts’ Ratings Updates for Jazz Pharmaceuticals $JAZZ  
01/16Jazz Pharmaceuticals $JAZZ PT Raised to $170 at Deutsche Bank Following Inves..
1
01/16$JAZZ - Jazz Pharmaceuticals #JAZZ Upgraded by Zacks Investment Research to H.. 
01/15Jazz Pharmaceuticals $JAZZ Upgraded to “Hold” at Zacks Investment Research  
01/15SunTrust Banks Lowers Jazz Pharmaceuticals FY2018 Earnings Estimates to $11.2.. 
More tweets
Qtime:191
News from SeekingAlpha
01/09 Jazz Pharmaceuticals (JAZZ) Presents At 36th Annual J.P. Morgan Healthcare Co..
01/06 Stocks to watch next week
01/04 JPMorgan Healthcare Conference next week
01/03 Premarket analyst action - new coverage - healthcare
2017 YOUR DAILY PHARMA SCOOP : Portola BLA Review Process Delayed, DelMar Soars, Alex..
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals PLC Technical Analysis Chart | JAZZ | IE00B4Q5ZN47 | 4-Traders
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 179 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher Chief Operating Officer & Executive Vice President
Matthew P. Young Chief Financial Officer & Executive Vice President
Karen L. Smith Chief Medical Officer & EVP-Research & Development
Paul Treacy Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
JAZZ PHARMACEUTICALS PLC11.54%8 981
ABBVIE3.75%163 379
MERCK KGAA2.15%14 691
KYOWA HAKKO KIRIN CO LTD-1.08%11 433
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD15.41%7 028
CONVATEC GROUP-7.98%5 161